Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnelArticle Published on 2023-02-012023-07-11 Journal: The Journal of hospital infection [Category] COVID19(2023년), [키워드] booster dose Breakthrough infection COVID-19 healthcare personnel SARS-CoV-2 vaccination. [DOI] 10.1016/j.jhin.2022.11.016 PMC 바로가기
Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines현재 사용 가능한 COVID-19 백신에 저항할 가능성이 있는 새로 분류된 관심 변종인 SARS-CoV-2 Mu에 대처하기 위한 전략Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adopted approach B.1 lineage B.1.621 BNT161b2 booster dose Characteristics coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine COVID-19 vaccine development Evidence exacerbated Genetic genomic Genomic surveillance global mass vaccination Health implementation infections Intervention Lineage mass vaccination Mu variant mutations Neutralizing non-pharmaceutical interventions (NPIs) NPIs potential risk public health measure public health measures Recombination reported required respiratory restrict SARS-CoV-2 SARS-CoV-2 B.1.621 SARS-CoV-2 virus sera shown Strains Strategy sub-lineage B.1.621.1 Surveillance survivor the SARS-CoV-2 virus therapeutic threat vaccination Vaccine vaccine breakthrough. Vaccine development variant variants [DOI] 10.1080/21645515.2022.2027197 PMC 바로가기 [Article Type] Article
Acceptance of the COVID-19 vaccine booster dose and associated factors among the elderly in China based on the health belief model (HBM): A national cross-sectional studyArticle Published on 2022-12-152023-07-11 Journal: Frontiers in Public Health [Category] COVID19(2023년), [키워드] booster dose COVID-19 Hesitancy old people vaccination. [DOI] 10.3389/fpubh.2022.986916 PMC 바로가기
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIVHIV 보균자에서 비활성화된 SARS-CoV-2 백신의 안전성 및 면역원성Observational Study Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] adverse event age Analysis binding domain booster dose CD4 CD4 count CD4 counts Cell COVID-19 declined Efficacy enrolled evaluated Factor Frequency Gender geometric GMT healthy control healthy controls HIV humoral humoral immune response IgG immune immune response Immunocompromised in both groups inactivated Inactivated vaccine less MBC memory B occurred Patient PLWH predicted prospective observational study reduced remained reported response responses robust Safety Safety. SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event Seven significantly vaccination Viral load with HIV [DOI] 10.1080/22221751.2022.2059401 PMC 바로가기 [Article Type] Observational Study
A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variantsDelta 및 Omicron 변종에 감염된 백신 접종자의 폐렴 및 바이러스 부하 예방에 대한 중국산 COVID-19 백신의 1차 및 추가 접종 효과에 대한 사례 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] administration age analysed association booster booster dose booster immunization calculate case study case-case study COVID-19 COVID-19 outbreak COVID-19 pneumonia COVID-19 vaccine Ct value Ct values Delta determine eligible evaluated immunization Infection infections less Logistic regression no difference no differences Odds ratio Odds ratios omicron pace Pneumonia real-world study. recipient reduced reduction SARS-CoV-2 viral load vaccination Vaccination Status variant Viral load [DOI] 10.1080/22221751.2022.2103455 PMC 바로가기 [Article Type] Article
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimodArticle Published on 2022-12-012022-11-15 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 진단, [키워드] binding antibody unit BNT162b2 mRNA BNT162b2 mRNA vaccine booster dose collected Control COVID-19 COVID-19 vaccine dose expressed fingolimod HCs humoral Humoral response IgG IgG antibody IgG level Laboratory mRNA mRNA vaccine Multiple multiple sclerosis Ocrelizumab Ocrelizumab. of BNT162b2 Patient positive predict quantified reported SARS-CoV-2 sclerosis serum sample severe adverse event socio-demographic threshold Tolerability treated Trimeric spike protein Vaccine vaccine dose variable [DOI] 10.1007/s00415-022-11296-4 PMC 바로가기
Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysisMeta-Analysis Published on 2022-12-012023-07-10 Journal: Expert review of vaccines [Category] COVID19(2023년), [키워드] booster dose Effectiveness omicron VOC Sars-Cov2 vaccine risk of hospitalization SARS-CoV2 vaccine symptomatic omicron infection Waning Immunity. [DOI] 10.1080/14760584.2022.2130773 PMC 바로가기 [Article Type] Meta-Analysis
Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical TrialClinical Trial Published on 2022-12-012023-07-10 Journal: Clinical therapeutics [Category] COVID19(2023년), [키워드] booster dose COVID-19 kidney transplant SARS-CoV-2 SpikoGen. [DOI] 10.1016/j.clinthera.2022.10.002 PMC 바로가기 [Article Type] Clinical Trial
Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021Research article Published on 2022-12-012022-10-05 Journal: Global Epidemiology [Category] 변종, [키워드] Analysis booster booster dose COVID-19 database deaths decrease delta variant Effectiveness ENhance Evolution finding France Hospitalization hospitalizations ICU admission infected individuals information National outcome performed Real-world estimates reduced remained reversed SARS-CoV-2 Spread survival symptomatic symptomatic infection symptomatic infections test-negative design vaccination Vaccine vaccine immunity variant variants waning immunity [DOI] 10.1016/j.gloepi.2022.100076 [Article Type] Research article